ideology-health
  • Our Solutions
  • About Us
  • ideology-health
    Privacy Policy
    Terms of Service

    IDEOlogy Health Ranks No. 772 on the 2025 Inc. 5000 Fastest-Growing Private Companies in America

    © 2025 IDEOlogy Health. All product names, logos, brands, trademarks and registered trademarks are property of their respective owners and their use(s) do not necessarily imply endorsement.

    Dr. Eric Singhi reviews 5-year efficacy of cemiplimab + chemotherapy in aNSCLC (Video 1/3)
    Sign up to watch this video

    Free access to all Sound Bites content

    Dr. Eric Singhi reviews 5-year efficacy of cemiplimab + chemotherapy in aNSCLC (Video 1/3)

    Published on: January 14, 2026


    E

    Eric Singhi , MD

    Medical Professional


    EMPOWER Squamous

    Related Videos
    Dr. Charu Aggarwal discusses the efficacy of datopotamab deruxtecan in pretreated mNSCLC  (Video 1/3)

    Dr. Charu Aggarwal discusses the efficacy of datopotamab deruxtecan in pretreated mNSCLC (Video 1/3)

    Charu Aggarwal, MD
    Dr. Eric Singhi reviews 5-year efficacy of cemiplimab + chemotherapy in aNSCLC (Video 1/3)

    Dr. Eric Singhi reviews 5-year efficacy of cemiplimab + chemotherapy in aNSCLC (Video 1/3)

    Eric Singhi , MD
    Dr. Joshua Zeidner reviews the data for revumenib in patients with NPM1-mutated AML (Video 3/3)

    Dr. Joshua Zeidner reviews the data for revumenib in patients with NPM1-mutated AML (Video 3/3)

    Joshua Zeidner, MD
    Dr. Hossein Borghaei describes the safety of nivo/ipi + chemo in patients with mNSCLC and the efficacy in patients who discontinue early.  (Video 3/3)

    Dr. Hossein Borghaei describes the safety of nivo/ipi + chemo in patients with mNSCLC and the efficacy in patients who discontinue early. (Video 3/3)

    Hossein Borghaei, MD
    Dr. Arvind Dasari gives an overview of ctDNA with a focus on why the data from Galaxy and Bespoke-CRC was pooled for surveillance (Video 1/3)

    Dr. Arvind Dasari gives an overview of ctDNA with a focus on why the data from Galaxy and Bespoke-CRC was pooled for surveillance (Video 1/3)

    Arvind Dasari, MD
    Dr. Melissa Johnson describes the safety of atezolizumab + lurbinectedin maintenance therapy in 1L ES-SCLC.  (Video 3/3)

    Dr. Melissa Johnson describes the safety of atezolizumab + lurbinectedin maintenance therapy in 1L ES-SCLC. (Video 3/3)

    Melissa Johnson